Factor P Antibody (Monoclonal - #1)

A murine monoclonal antibody to an epitope on Factor P.


Product Specifications

Citations10
Clonality

Monoclonal

Immnogen

Purified human protein.

Applications

See citations and technical data sheet for application info.

Concentration1.0-1.2 mg/mL
ConjugateUnconjugated
Cross Reactivity

Human

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.
Catalog NumberA233
Catalog Number (CE)N/A
Size100 µl
Price (USD)$365.00
Price (EURO)330,00 €

Contact us

US Phone+1 (858) 552 1100
EU Phone+353 (91) 412 474
US Emailcontact-us@quidelortho.com
EU Emailcontact-emea@quidelortho.com

Specifications

Description

A murine monoclonal antibody to an epitope on Factor P.

Size

100 µl

Concentration1.0-1.2 mg/mL
ApplicationsSee citations and technical data sheet for application info.
FormLiquid. Borate Buffered Saline (pH 8.4 ± 0.2), with ≤ 0.1% Sodium Azide.
ClonalityMonoclonal
Immunogen

Purified human protein.

ConjugateUnconjugated
Cross ReactivityHuman
Isotype

IgG1k

Purity

≥ 95% by SDS PAGE

SourceMouse
Specificity

This monoclonal antibody was raised against purified Factor P. It inhibits the function of Factor P.

Storage

Short term (30 days) 4˚C. Long term at or below –20˚C.

Background

The function of Properdin (Factor P) is to stabilize the alternative pathway convertase. Its binding to C3bBb extends the half-life of the complex. The concentration in plasma is approximately 20 μg/mL. Factor P has a molecular weight of 224 kDa, consisting of four identical chains of approximately 53 kDa molecular weight. The alternative complement pathway provides innate protection against microbial agents in the absence of specific antibody. The activation of this complement pathway can be triggered by a variety of substances, including microbial polysaccharides or lipids, gram-negative bacterial lipopolysaccharides, and surface determinants present on some viruses, parasites, virally infected mammalian cells and cancer cells. In autoimmune diseases, the alternative complement pathway may contribute directly to tissue damage.

Citations

TitleYearApplicationsSample SpeciesSampleSample Details

Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.

2020Hemolytic AssayRabbit

Red Blood Cells

N/A

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.

2019ELISAHuman

Plasma

N/A

Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.

2019ELISAHuman

Serum

N/A

Properdin binding to complement activating surfaces depends on initial C3b deposition

2017ELISA, WBHuman

Serum

N/A

Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo.

2017WBHuman

Plasma

SPIO nanoworms

Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo.

2017WBHuman

Serum

SPIO nanoworms

A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples.

2014ELISAHuman

Plasma

N/A

The Role of Properdin in Zymosan- And Escherichia Coli-Induced Complement Activation.

2013FCHuman

Serum

N/A

Combined roles of human IgG subclass, alternative complement pathway activation, and epitope density in the bactericidal activity of antibodies to meningococcal factor h binding protein

2012FCHuman

Serum

Meningococcal infected

Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans.

2011WBHuman

Serum

N/A